Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Grepafloxacin: microbiological properties.

Michael S. Marriott1

  • 1Glaxo Wellcome, Medicines Research Centre, Verona, Italy.

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|March 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Impact of low-dose chest CT and multiplex PCR on antibiotic usage for community-acquired pneumonia: multicentre prospective controlled before-after study with cluster randomisation (CAP-NEXT study).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Clinical Microbiology and Infection: how did we do in 2025?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Automate the work, not the decision: aligning expectations for AI in clinical microbiology.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Doxycycline prophylaxis and gonococcal resistance: reassurance, residual signals, and the case for surveillance.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Oral metronidazole versus clindamycin to treat bacterial vaginosis in pregnancies at risk for preterm labor.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Efficacy and safety of a radiographic severity-stratified all-oral short treatment regimen for multidrug/rifampicin-resistant tuberculosis in China: An open-label, multi-center,randomized controlled, non-inferiority trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
See all related articles

Grepafloxacin, a novel fluoroquinolone, shows potent activity against various bacteria, including drug-resistant strains. Its broad-spectrum efficacy and bactericidal action offer significant advantages over existing antibiotics.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Grepafloxacin is a novel, broad-spectrum fluoroquinolone antibiotic.
  • It features a unique methyl-substituted piperazine at the 7-position, enhancing its properties.
  • Grepafloxacin is a water-soluble racemate with equivalent activity from both stereoisomers.

Purpose of the Study:

  • To evaluate the antimicrobial activity and pharmacological profile of grepafloxacin.
  • To investigate its mechanism of action and efficacy against resistant bacterial strains.
  • To compare its therapeutic potential against established antibiotic classes.

Main Methods:

  • In vitro susceptibility testing against a range of bacterial pathogens.
  • Assessment of interaction with bacterial topoisomerases II and IV.

Related Experiment Videos

  • Evaluation of the NorA efflux mechanism in Staphylococcus aureus.
  • In vivo studies using animal models of respiratory tract infections.

    • Main Results:

    • Grepafloxacin exhibits potent in vitro activity against Gram-positive (streptococci, staphylococci) and Gram-negative respiratory pathogens, atypical pathogens, and STD pathogens.
    • It effectively inhibits bacterial topoisomerases II and IV.
    • Grepafloxacin is not recognized by the NorA efflux mechanism, retaining activity against some fluoroquinolone-resistant Staphylococcus aureus strains.
    • Bactericidal activity at concentrations close to the minimum inhibitory concentration (MIC) was observed, unlike macrolides.
    • In vitro efficacy translated to positive outcomes in animal models of respiratory tract infections, with sustained concentrations above MICs.

    Conclusions:

    • Grepafloxacin demonstrates significant broad-spectrum antimicrobial activity, including against resistant strains.
    • Its unique mechanism and favorable pharmacokinetic profile suggest it is an important advancement over older quinolones and other antibiotic classes.
    • Grepafloxacin offers a promising therapeutic option for various bacterial infections, particularly respiratory tract infections.